TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.